Review on clinical trials of targeted treatments in malignant mesothelioma

[1] Steele JPC(2005)Prognostic factors in mesothelioma Lung Cancer 49 S49-S52

[2] Klabatsa A(1997)Malignant mesothelioma in south east England: clinicopathological experience of 272 cases Thorax 52 507-512

[3] Fennell DA(2005)New agents in the management of advanced mesothelioma Semin Oncol 32 336-350

[4] Palläska A(2008)Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma Br J Cancer 99 44-50

[5] Sheaff MT(2003)Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636-2644

[6] Evans MT(2010)Second-line treatment for malignant pleural mesothelioma Cancer Treat Rev 36 24-32

[7] Yates DH(2001)Angiogenesis is an independent prognostic factor in malignant mesothelioma Br J Cancer 85 863-868

[8] Corrin B(2005)Serum PDGF-AB in pleural mesothelioma Tumour Biol 26 221-226

[9] Stidolph PN(1998)Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders Hum Pathol 29 498-504

[10] Browne K(2003)Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma Am J Clin Oncol 22 912-86

[1] Steele JPC(2005)Prognostic factors in mesothelioma Lung Cancer 49 S49-S52

[2] Klabatsa A(1997)Malignant mesothelioma in south east England: clinicopathological experience of 272 cases Thorax 52 507-512

[3] Fennell DA(2005)New agents in the management of advanced mesothelioma Semin Oncol 32 336-350

[4] Palläska A(2008)Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma Br J Cancer 99 44-50

[5] Sheaff MT(2003)Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636-2644

[6] Evans MT(2010)Second-line treatment for malignant pleural mesothelioma Cancer Treat Rev 36 24-32

[7] Yates DH(2001)Angiogenesis is an independent prognostic factor in malignant mesothelioma Br J Cancer 85 863-868

[8] Corrin B(2005)Serum PDGF-AB in pleural mesothelioma Tumour Biol 26 221-226

[9] Stidolph PN(1998)Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders Hum Pathol 29 498-504

[10] Browne K(2003)Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma Am J Clin Oncol 22 912-86